October 20, 2021
Company Info
| Industry | Pharmaceuticals: Other |
|---|---|
| Sector | Health Technology |
| Employees | 24 |
| CEO | Mr. Joseph P. Hagan |
| Address | 4224 Campus Point Court Suite 210, San Diego, CA 92121 |
|---|---|
| Phone | 1.858.202.6300 |
| Website | www.regulusrx.com |
Regulus Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of drugs targeting microRNAs. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease. RGLS4326 is an anti-miR targeting miR-17 in Phase I clinical trial for the treatment of autosomal dominant polycystic kidney disease. The firm is also developing a pipeline of preclinical drug product candidates in renal, hepatic, and central nervous systems diseases. The company was founded on September 5, 2007 and is headquartered in San Diego, CA.
Competitors
| Company Name | 3 Month %Change |
1 Year %Change |
|---|---|---|
| Regulus Therapeutics, Inc. | -33.10% | -4.92% |
| ViewRay, Inc. | 4.35% | 112.66% |
| Icosavax, Inc. | n/a | n/a |
| Connect Biopharma Holdings Ltd. | -32.98% | n/a |
| iTeos Therapeutics, Inc. | 14.68% | 23.46% |
Statement Summary
as of 4:00 ET PM 10/18/2021| Total Assets (MRQ) | 49.5 M |
|---|---|
| Total Liabilities (MRQ) | 12.7 M |
| Shareholders’ Equity (MRQ) | 36.8 M |
| Total Revenue (Annual) | n/a |
| Net Income (Annual) | -6.0 M |
Earnings And Estimates
as of 4:00 ET PM 10/18/2021
| Current Qtr EPS Estimate | -0.08 |
|---|---|
| Current FY EPS Estimate | -0.31 |
| Long Term EPS Growth Estimate | n/a |
| Next Expected Earnings Date | 11/11/2021 |
RGLS vs S&P 500
as of 10/18/2021| Relative To S&P 500 |
RGLS | |
|---|---|---|
| 4 Weeks | n/a | n/a |
| 12 Weeks | n/a | n/a |
| YTD | n/a | n/a |
Earnings Surprises
as of 4:00 ET PM 10/18/2021| Fiscal Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| 06/2021 | -0.08 | -0.08 | 0.00% |
| 03/2021 | -0.09 | -0.08 | -11.11% |
| 12/2020 | -0.14 | -0.03 | -78.57% |
| 09/2020 | -0.21 | -0.04 | -80.72% |
| 06/2020 | -0.11 | -0.23 | +113.95% |
| 03/2020 | -0.12 | -0.25 | +108.33% |
| 12/2019 | -0.24 | -0.23 | -4.17% |
| 09/2019 | -0.26 | -0.26 | -0.95% |
Financial Strength
as of 4:00 ET PM 10/18/2021| Pre-Tax Margin | 0.00 |
|---|---|
| Net Margin | 0.00 |
| Operating Margin | 0.00 |
| Return On Equity | -65.59 |
| Return On Assets | -37.56 |
| Inventory Turnover (TTM) | 0.00 |
| Sales Growth (MRQ) | -13.58 |
Ratios
as of 4:00 PM ET 10/18/2021| Price/Earnings (TTM) | n/a |
|---|---|
| Price/Book (MRQ) | 1.14 |
| Price/Cash Flow (TTM) | 0.00 |
| Book Value (MRQ) | 0.42 |
| Quick Ratio (MRQ) | 4.32 |
| Current Ratio (MRQ) | 4.32 |
| Total Debt/Equity (MRQ) | 0.20 |
Short Interest
as of 4:00 PM ET 10/19/2021| % Short - 0.00% | |
| % Remaining Float - 100.00% |
| Current | Last Month | |
|---|---|---|
| Short Interest Date | n/a | n/a |
| Short Interest Shares | 0 | 0 |
| Short Interest Ratio | 0.0 | 0.0 |
M Y M Y
Total Assets 0,0.00 0,0.00
Total Liabilities 0,0.00 0,0.00
Total Equity 0,0.00 0,0.00
M Y M Y
Total Revenue 0,0.00 0,0.00
EBT Exc.
Unusual Items
0,0.00
0,0.00
Net Income 0,0.00 0,0.00
M Y M Y
Cash from
Operations
0,0.00
0,0.00
Cash from
Activities
0,0.00
0,0.00
Cash from
Fin. Activities
0,0.00
0,0.00
TOTAL ASSETS |
TOTAL LIABILITIES |
TOTAL EQUITY |
|---|---|---|
Balance Sheet
| M Y | ||||
|---|---|---|---|---|
| ASSETS | ||||
| Cash And Equivalents | 0,0.00 | |||
| Receivables | 0,0.00 | |||
| Inventories | 0,0.00 | |||
| Other Current Assets | 0,0.00 | |||
| Total Current Assets | 0,0.00 | |||
| Property, Plant & Equipment, Gross | 0,0.00 | |||
| Accumulated Depreciation & Depletion | 0,0.00 | |||
| Property, Plant & Equipment, Net | 0,0.00 | |||
| Intangibles | 0,0.00 | |||
| Other Non-Current Assets | 0,0.00 | |||
| Total Non-Current Assets | 0,0.00 | |||
| TOTAL ASSETS | 0,0.00 | |||
| Liabilities & Shareholder Equity | ||||
| Accounts Payable | 0,0.00 | |||
| Short Term Debt | 0,0.00 | |||
| Total Current Liabilities | 0,0.00 | |||
| Long Term Debt | 0,0.00 | |||
| Deferred Income Taxes | 0,0.00 | |||
| Other Non-Current Liabilities | 0,0.00 | |||
| Minority Interest | 0,0.00 | |||
| Total Non-Current Liabilities | 0,0.00 | |||
| Preferred Stock Equity | 0,0.00 | |||
| Common Stock Equity | 0,0.00 | |||
| Common Par | 0,0.00 | |||
| Additional Paid In Capital | 0,0.00 | |||
| Cumulative Translation Adjustment | 0,0.00 | |||
| Retained Earnings | 0,0.00 | |||
| Treasury Stock | 0,0.00 | |||
| Other Equity Adjustments | 0,0.00 | |||
| Total Capitalization | 0,0.00 | |||
| TOTAL EQUITY | 0,0.00 | |||
| TOTAL LIABILITIES & STOCK EQUITY | 0,0.00 | |||
| Total Common Shares Outstanding | 0,0.00 | |||
| Preferred Shares | 0,0.00 | |||
| Treasury Shares | 0,0.00 | |||
| Basic Weighted Shares Outstanding | 0,0.00 | |||
| Diluted Weighted Shares Outstanding | 0,0.00 | |||
| Number Of Employees | 0,0.00 | |||
| Number Of Part-Time Employees | 0,0.00 | |||
TOTAL REVENUES |
EBT Excluding Unusual Items |
NET INCOME |
|---|---|---|
Income Statement
| M Y | |
|---|---|
| Sales | 0,0.00 |
| Cost Of Sales | 0,0.00 |
| Gross Operating Profit | 0,0.00 |
| Selling, General, And Administrative Expenses | 0,0.00 |
| Research & Development | 0,0.00 |
| Operating Income Before D & A (EBITDA) | 0,0.00 |
| Depreciation & Amortization | 0,0.00 |
| Interest Income | 0,0.00 |
| Other Income - Net | 0,0.00 |
| Special Income / Charges | 0,0.00 |
| Total Income Before Interest Expenses (EBIT) | 0,0.00 |
| Interest Expense | 0,0.00 |
| Pre-Tax Income | 0,0.00 |
| Income Taxes | 0,0.00 |
| Minority Interest | 0,0.00 |
| Net Income From Continuing Operations | 0,0.00 |
| Net Income From Discontinued Operations | 0,0.00 |
| Net Income From Total Operations | 0,0.00 |
| Extraordinary Income/Losses | 0,0.00 |
| Income From Cum. Effect Of Acct. Change | 0,0.00 |
| Income From Tax Loss Carryforward | 0,0.00 |
| Other Gains / Losses | 0,0.00 |
| Total Net Income | 0,0.00 |
| Normalized Income (Net Income From Continuing Operations, Ex. Special Income / Charge) |
0,0.00 |
| Preferred Dividends | 0,0.00 |
| Net Income Available To Common | 0,0.00 |
| Basic EPS From Continuing Ops. | 0,0.00 |
| Basic EPS From Discontinued Ops. | 0,0.00 |
| Basic EPS From Total Operations | 0,0.00 |
| Basic EPS From Extraordinary Inc. | 0,0.00 |
| Basic EPS From Cum Effect Of Accounting Change | 0,0.00 |
| Basic EPS From Tax Loss Carryf'd. | 0,0.00 |
| Basic EPS From Other Gains (Losses) | 0,0.00 |
| Basic EPS, Total | 0,0.00 |
| Basic Normalized Net Income/Share | 0,0.00 |
| EPS From Continuing Ops. | 0,0.00 |
| EPS From Discontinued Ops | 0,0.00 |
| EPS From Total Ops. | 0,0.00 |
| EPS From Extraord. Inc. | 0,0.00 |
| EPS From Cum Effect of Accounting Change | 0,0.00 |
| EPS From Tax Loss Carfd. | 0,0.00 |
| EPS From Other Gains (L) | 0,0.00 |
| EPS, Total | 0,0.00 |
| Diluted Normalized Net Inc/Shr (Net Income From Continuing Operations, Ex. Special Income / Charge) |
0,0.00 |
| Dividends Paid Per Share | 0,0.00 |
CASH FROM OPERATIONS |
CASH FROM INVESTING ACTIVITIES |
CASH FROM FINANCING ACTIVITIES |
|---|---|---|
Cash Flow Statement
| M Y | ||||
|---|---|---|---|---|
| Cash Flow From Operating Activities | ||||
| Net Income (Loss) | 0,0.00 | |||
| Operating Gains/Losses | 0,0.00 | |||
| Gross Operating Profit | 0,0.00 | |||
| (Increase) Decrease In Receivables | 0,0.00 | |||
| (Increase) Decrease In Inventories | 0,0.00 | |||
| (Increase) Decrease In Other Current Assets | 0,0.00 | |||
| (Decrease) Increase In Other Current Liabilities | 0,0.00 | |||
| (Increase) Decrease In Other Working Capital | 0,0.00 | |||
| Other Non-Cash Items | 0,0.00 | |||
| Net Cash From Continuing Operations | 0,0.00 | |||
| Net Cash From Discontinued Operations | 0,0.00 | |||
| Cash Provided By Investing Activities | ||||
| Net Cash From Total Operating Activities | 0,0.00 | |||
| Sale Of Property, Plant & Equipment | 0,0.00 | |||
| Cash Used For Investing Activities | ||||
| Sale Of Short-Term Investments | 0,0.00 | |||
| Purchases Of Property, Plant & Equipment | 0,0.00 | |||
| Acquisitions | 0,0.00 | |||
| Purchases Of Short-Term Investments | 0,0.00 | |||
| Other Cash From Investing Activities | 0,0.00 | |||
| Cash Provided by Financing Activities | ||||
| Net Cash From Investing Activities | 0,0.00 | |||
| Issuance Of Debt | 0,0.00 | |||
| Cash Used For Financing Activities | ||||
| Issuance Of Capital Stock | 0,0.00 | |||
| Repayment Of Long-Term Debt | 0,0.00 | |||
| Repurchase Of Capital Stock | 0,0.00 | |||
| Payment Of Cash Dividends | 0,0.00 | |||
| Other Financing Charges, Net | 0,0.00 | |||
| Net Cash From Financing Activities | 0,0.00 | |||
| Effect Of Exchange Rate Changes | 0,0.00 | |||
| Net Change In Cash & Cash Equivalents | 0,0.00 | |||
Earnings Estimates
as of 4:00 ET PM 10/18/2021| Current Qtr (09/2021) |
Next Qtr (12/2021) |
|
|---|---|---|
| Consensus Estimate | $-0.08 | $-0.08 |
| # of Estimates | 4 | 4 |
| High Estimate | $-0.07 | $-0.07 |
| Low Estimate | $-0.09 | $-0.09 |
| Year Ago EPS | $-0.04 | $-0.03 |
| Year Over Year Growth Estimate | 93.75% | 170.76% |
| Current Yr (12/2021) |
Next Yr (12/2022) |
|
|---|---|---|
| Consensus Estimate | $-0.31 | $-0.31 |
| # of Estimates | 4 | 4 |
| High Estimate | $-0.30 | $-0.25 |
| Low Estimate | $-0.34 | $-0.37 |
| Year Ago EPS | $-0.45 | $-0.31 |
| Year Over Year Growth Estimate | -30.56% | 0.00% |
| Current Qtr (09/2021) |
Next Qtr (12/2021) |
Current Year (12/2021) |
Next Year (12/2022) |
|
|---|---|---|---|---|
| Consensus Estimate | $-0.08 | $-0.08 | $-0.31 | $-0.31 |
| # of Estimates | 4 | 4 | 4 | 4 |
| High Estimate | $-0.07 | $-0.07 | $-0.30 | $-0.25 |
| Low Estimate | $-0.09 | $-0.09 | $-0.34 | $-0.37 |
| Year Ago EPS | $-0.04 | $-0.03 | $-0.45 | $-0.31 |
| Year Over Year Growth Estimate | 93.75% | 170.76% | -30.56% | 0.00% |
Insider Information Summary
as of 09/30/2021| % Insiders - 11.70% | |
| % Remaining Total Shares - 88.30% |
| Current | 1 Month | |
|---|---|---|
| Net Insider Transaction | 0.00 | 0.00 |
| Shares Bought | 0.00 | 0.00 |
| Shares Sold | 0.00 | 0.00 |
Insider Activity
| Transaction Date | Insider/Title | Transaction Type | Market Value | Shares | Average Price | Current Holdings | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Learn to Trade Like a Pro
Master The Market with the Help of Our Financial Experts
LATEST NEWS
AstraZeneca drops partnership with Regulus after ditching drug
Jun 13, 2017 1:12 PM EDT
Latest News
Regulus Therapeutics To Present At The Oppenheimer Rare & Orphan Disease Summit
May 14, 2021 4:07 PM EDT
Regulus Therapeutics To Present At The 20th Annual Needham Virtual Healthcare Conference
Apr 7, 2021 8:07 AM EDT
Regulus Announces Addition To Board Of Directors
Jan 27, 2021 8:07 AM EST
Regulus Therapeutics To Present At The H.C. Wainwright Virtual BioConnect Conference
Jan 5, 2021 8:07 AM EST
Regulus Therapeutics Announces Closing Of $19.4 Million Private Placement Of Equity
Dec 8, 2020 8:07 AM EST
Regulus Therapeutics Collaborates With Bio-Techne For Biomarker Development
Dec 2, 2020 7:00 AM EST
Regulus Therapeutics Announces Private Placement Of Equity
Dec 1, 2020 8:35 AM EST
Regulus Therapeutics Announces Receipt Of $5 Million Milestone And Material Payments From Sanofi
Oct 13, 2020 8:07 AM EDT
Regulus Therapeutics To Present At The 2020 Wells Fargo Virtual Healthcare Conference
Sep 3, 2020 8:07 AM EDT
Regulus Therapeutics Announces Restructuring Of Sanofi And Oxford Loan Agreements
Aug 31, 2020 8:07 AM EDT
Regulus Therapeutics To Present At The 2020 Wedbush PacGrow Healthcare Virtual Conference
Aug 6, 2020 8:07 AM EDT
Regulus Therapeutics Appoints Denis Drygin, Ph.D., As Chief Scientific Officer
Aug 3, 2020 8:07 AM EDT
Recent Articles from TheStreet
United Airlines Third-Quarter Sales Beat Estimates
United Airlines shares rose after hours Tuesday as it released third-quarter earnings that showed its sales beat analyst estimates.
Deporre: Bitcoin Miners Drawing Fresh Interest
Ahead of the first bitcoin ETF, 'Rev Shark' saw lots of intensity in the market.
Cramer's Mad Money Recap 10/19: Chevron, Wells Fargo, Nvidia
Jim Cramer take a look at the stocks he says are poised to profit even when inflation is rising.
Canadian National Jumps on CEO Departure Announcement
Campaign for new management by investor group followed failed bid for Kansas City Southern
BlackRock's Rieder: Stocks Could Rise Up to 10% by Year-End
'Could you get another 5 to 8% out of the market, … maybe even 10%? I think so,' Blackrock's CIO Rick Rieder told CNBC.
Heller: Triple Net Active Portfolio Wins by a Nose
Strategy of selecting companies at low net current asset values tops benchmarks.
Facebook Settles DOJ Lawsuit And Labor Department Audit
Facebook settles a lawsuit by the Department of Justice and an audit by the Department of Labor over the PERM hiring program.
CLOSE
CLOSE
CLOSE
CLOSE